Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
48
APLS Quote, Financials, Valuation and Earnings
Last price:
$22.81
Seasonality move
:
5.14%
Day range:
$21.64 - $22.81
52-week range:
$16.10 - $30.48
Dividend yield:
0%
P/E ratio:
74.75x
P/S ratio:
2.76x
P/B ratio:
7.00x
Volume:
1.3M
Avg. volume:
3.3M
1-year change:
-19.69%
Market cap:
$2.8B
Revenue:
$781.4M
EPS (TTM):
$0.30
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
APLS
Apellis Pharmaceuticals, Inc.
|
$199.3M | -$0.40 | 15.96% | -35.6% | $33.95 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
$807.3M | $0.18 | 6.58% | 416.62% | $15.20 |
|
FOLD
Amicus Therapeutics, Inc.
|
$185M | $0.18 | 29.62% | 267.32% | $14.50 |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$156.1M | -$1.24 | 46.3% | -36.26% | $91.13 |
|
SRPT
Sarepta Therapeutics, Inc.
|
$391M | -$0.77 | -49.33% | -91.57% | $21.43 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
APLS
Apellis Pharmaceuticals, Inc.
|
$22.20 | $33.95 | $2.8B | 74.75x | $0.00 | 0% | 2.76x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$339.37 | $457.00 | $45B | 150.36x | $0.00 | 0% | 12.20x |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
$14.60 | $15.20 | $4.6B | 1,035.46x | $0.00 | 0% | 1.59x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.34 | $14.50 | $4.5B | -- | $0.00 | 0% | 7.34x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$82.22 | $91.13 | $13.3B | -- | $0.00 | 0% | 14.00x |
|
SRPT
Sarepta Therapeutics, Inc.
|
$18.38 | $21.43 | $1.9B | 20.50x | $0.00 | 0% | 0.79x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
APLS
Apellis Pharmaceuticals, Inc.
|
54.23% | 0.668 | 16.61% | 2.96x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
104.25% | 0.556 | 83.58% | 1.31x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.293 | 18.22% | 1.91x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
76.83% | 2.779 | 19.43% | 2.51x |
|
SRPT
Sarepta Therapeutics, Inc.
|
48.64% | -0.463 | 61.92% | 1.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
APLS
Apellis Pharmaceuticals, Inc.
|
$433.7M | $223.2M | 6.35% | 18.94% | 48.67% | $108.3M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
$274M | $72.8M | 2.24% | -587.3% | 9.28% | $96M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$151.5M | -$160.2M | -9.92% | -43.01% | -102.21% | -$138.4M |
|
SRPT
Sarepta Therapeutics, Inc.
|
$230.1M | -$62.9M | -10.24% | -20.67% | -15.75% | -$55.6M |
Apellis Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns APLS or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of 47.04% compared to Apellis Pharmaceuticals, Inc.'s net margin of 16.99%. Apellis Pharmaceuticals, Inc.'s return on equity of 18.94% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital APLSApellis Pharmaceuticals, Inc.94.58% $1.66 $876.5M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About APLS or ALNY?
Apellis Pharmaceuticals, Inc. has a consensus price target of $33.95, signalling upside risk potential of 52.92%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 34.66%. Given that Apellis Pharmaceuticals, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Apellis Pharmaceuticals, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APLSApellis Pharmaceuticals, Inc.11 7 1 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is APLS or ALNY More Risky?
Apellis Pharmaceuticals, Inc. has a beta of 0.256, which suggesting that the stock is 74.354% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock APLS or ALNY?
Apellis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APLS or ALNY?
Apellis Pharmaceuticals, Inc. quarterly revenues are $458.6M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Apellis Pharmaceuticals, Inc.'s net income of $215.7M is higher than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Apellis Pharmaceuticals, Inc.'s price-to-earnings ratio is 74.75x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 150.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals, Inc. is 2.76x versus 12.20x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APLSApellis Pharmaceuticals, Inc.2.76x 74.75x $458.6M $215.7M ALNYAlnylam Pharmaceuticals, Inc.12.20x 150.36x $1.1B $186.4M
-
Which has Higher Returns APLS or AMRX?
Amneal Pharmaceuticals, Inc. has a net margin of 47.04% compared to Apellis Pharmaceuticals, Inc.'s net margin of 2.31%. Apellis Pharmaceuticals, Inc.'s return on equity of 18.94% beat Amneal Pharmaceuticals, Inc.'s return on equity of -587.3%.
Company Gross Margin Earnings Per Share Invested Capital APLSApellis Pharmaceuticals, Inc.94.58% $1.66 $876.5M AMRXAmneal Pharmaceuticals, Inc.34.92% $0.01 $2.6B -
What do Analysts Say About APLS or AMRX?
Apellis Pharmaceuticals, Inc. has a consensus price target of $33.95, signalling upside risk potential of 52.92%. On the other hand Amneal Pharmaceuticals, Inc. has an analysts' consensus of $15.20 which suggests that it could grow by 4.11%. Given that Apellis Pharmaceuticals, Inc. has higher upside potential than Amneal Pharmaceuticals, Inc., analysts believe Apellis Pharmaceuticals, Inc. is more attractive than Amneal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APLSApellis Pharmaceuticals, Inc.11 7 1 AMRXAmneal Pharmaceuticals, Inc.2 0 0 -
Is APLS or AMRX More Risky?
Apellis Pharmaceuticals, Inc. has a beta of 0.256, which suggesting that the stock is 74.354% less volatile than S&P 500. In comparison Amneal Pharmaceuticals, Inc. has a beta of 1.356, suggesting its more volatile than the S&P 500 by 35.638%.
-
Which is a Better Dividend Stock APLS or AMRX?
Apellis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amneal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amneal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APLS or AMRX?
Apellis Pharmaceuticals, Inc. quarterly revenues are $458.6M, which are smaller than Amneal Pharmaceuticals, Inc. quarterly revenues of $784.5M. Apellis Pharmaceuticals, Inc.'s net income of $215.7M is higher than Amneal Pharmaceuticals, Inc.'s net income of $18.1M. Notably, Apellis Pharmaceuticals, Inc.'s price-to-earnings ratio is 74.75x while Amneal Pharmaceuticals, Inc.'s PE ratio is 1,035.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals, Inc. is 2.76x versus 1.59x for Amneal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APLSApellis Pharmaceuticals, Inc.2.76x 74.75x $458.6M $215.7M AMRXAmneal Pharmaceuticals, Inc.1.59x 1,035.46x $784.5M $18.1M
-
Which has Higher Returns APLS or FOLD?
Amicus Therapeutics, Inc. has a net margin of 47.04% compared to Apellis Pharmaceuticals, Inc.'s net margin of 10.24%. Apellis Pharmaceuticals, Inc.'s return on equity of 18.94% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital APLSApellis Pharmaceuticals, Inc.94.58% $1.66 $876.5M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About APLS or FOLD?
Apellis Pharmaceuticals, Inc. has a consensus price target of $33.95, signalling upside risk potential of 52.92%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.12%. Given that Apellis Pharmaceuticals, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Apellis Pharmaceuticals, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APLSApellis Pharmaceuticals, Inc.11 7 1 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is APLS or FOLD More Risky?
Apellis Pharmaceuticals, Inc. has a beta of 0.256, which suggesting that the stock is 74.354% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.857%.
-
Which is a Better Dividend Stock APLS or FOLD?
Apellis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APLS or FOLD?
Apellis Pharmaceuticals, Inc. quarterly revenues are $458.6M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Apellis Pharmaceuticals, Inc.'s net income of $215.7M is higher than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Apellis Pharmaceuticals, Inc.'s price-to-earnings ratio is 74.75x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals, Inc. is 2.76x versus 7.34x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APLSApellis Pharmaceuticals, Inc.2.76x 74.75x $458.6M $215.7M FOLDAmicus Therapeutics, Inc.7.34x -- $169.1M $17.3M
-
Which has Higher Returns APLS or IONS?
Ionis Pharmaceuticals, Inc. has a net margin of 47.04% compared to Apellis Pharmaceuticals, Inc.'s net margin of -82.06%. Apellis Pharmaceuticals, Inc.'s return on equity of 18.94% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.
Company Gross Margin Earnings Per Share Invested Capital APLSApellis Pharmaceuticals, Inc.94.58% $1.66 $876.5M IONSIonis Pharmaceuticals, Inc.96.67% -$0.81 $2.7B -
What do Analysts Say About APLS or IONS?
Apellis Pharmaceuticals, Inc. has a consensus price target of $33.95, signalling upside risk potential of 52.92%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $91.13 which suggests that it could grow by 10.83%. Given that Apellis Pharmaceuticals, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Apellis Pharmaceuticals, Inc. is more attractive than Ionis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APLSApellis Pharmaceuticals, Inc.11 7 1 IONSIonis Pharmaceuticals, Inc.10 6 0 -
Is APLS or IONS More Risky?
Apellis Pharmaceuticals, Inc. has a beta of 0.256, which suggesting that the stock is 74.354% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.94%.
-
Which is a Better Dividend Stock APLS or IONS?
Apellis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APLS or IONS?
Apellis Pharmaceuticals, Inc. quarterly revenues are $458.6M, which are larger than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Apellis Pharmaceuticals, Inc.'s net income of $215.7M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Apellis Pharmaceuticals, Inc.'s price-to-earnings ratio is 74.75x while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals, Inc. is 2.76x versus 14.00x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APLSApellis Pharmaceuticals, Inc.2.76x 74.75x $458.6M $215.7M IONSIonis Pharmaceuticals, Inc.14.00x -- $156.7M -$128.6M
-
Which has Higher Returns APLS or SRPT?
Sarepta Therapeutics, Inc. has a net margin of 47.04% compared to Apellis Pharmaceuticals, Inc.'s net margin of -45.06%. Apellis Pharmaceuticals, Inc.'s return on equity of 18.94% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.
Company Gross Margin Earnings Per Share Invested Capital APLSApellis Pharmaceuticals, Inc.94.58% $1.66 $876.5M SRPTSarepta Therapeutics, Inc.57.63% -$1.80 $2.6B -
What do Analysts Say About APLS or SRPT?
Apellis Pharmaceuticals, Inc. has a consensus price target of $33.95, signalling upside risk potential of 52.92%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $21.43 which suggests that it could grow by 16.62%. Given that Apellis Pharmaceuticals, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Apellis Pharmaceuticals, Inc. is more attractive than Sarepta Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APLSApellis Pharmaceuticals, Inc.11 7 1 SRPTSarepta Therapeutics, Inc.7 14 3 -
Is APLS or SRPT More Risky?
Apellis Pharmaceuticals, Inc. has a beta of 0.256, which suggesting that the stock is 74.354% less volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.731%.
-
Which is a Better Dividend Stock APLS or SRPT?
Apellis Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apellis Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APLS or SRPT?
Apellis Pharmaceuticals, Inc. quarterly revenues are $458.6M, which are larger than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. Apellis Pharmaceuticals, Inc.'s net income of $215.7M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, Apellis Pharmaceuticals, Inc.'s price-to-earnings ratio is 74.75x while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apellis Pharmaceuticals, Inc. is 2.76x versus 0.79x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APLSApellis Pharmaceuticals, Inc.2.76x 74.75x $458.6M $215.7M SRPTSarepta Therapeutics, Inc.0.79x 20.50x $399.4M -$179.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
73
HYMC alert for Feb 19
Hycroft Mining Holding Corp. [HYMC] is up 3.81% over the past day.
Buy
57
GLBE alert for Feb 19
Global-e Online Ltd. [GLBE] is up 4.19% over the past day.
Sell
37
ACLS alert for Feb 20
Axcelis Technologies, Inc. [ACLS] is down 1.71% over the past day.
